A pair of notable news items have emerged concerning the Indiana Biosciences Research Institute (IBRI), a non-profit, industry-led effort whose stakeholders include key companies such as Biomet, Cook Medical, Dow AgroSciences, Eli Lilly & Co., Indiana University Health and Roche Diagnostics — along with the State of Indiana, BioCrossroads and university collaborators such as Indiana, Purdue and Notre Dame.
One involves the appointment of industry executive and entrepreneur David A. Broecker as IBRI’s president and CEO. Broecker will help guide IBRI, which was formed in May 2013, in finding a permanent headquarters, building an operations team, securing key research recruits and launching collaborative research efforts later this year.
“I am extremely excited about the opportunity to build a one-of-a-kind research institute in Indiana and to be working with one of the world’s most successful and respected real estate development firms known for building thriving innovation communities.”
— David Broecker, president and CEO, Indiana Biosciences Research Institute
Additionally, IBRI is finalizing plans to lease 25,000 square feet of space at IU’s Biotechnology Research and Training Center (BRTC), which is north of the IUPUI medical school campus off 16th Street in Indianapolis. IBRI also hired Wexford Science and Technology to lead development activities that include finding a permanent home and planning an innovation district with IBRI as a main catalyst.
Read more here: